|
In the Phase III DUPLEX Study, Filspari reduced proteinuria by 46% and irbesartan by 30% over 108 weeks.
|
 |
|
The FDA has scheduled a decision date for 10 October 2026 under the Prescription Drug User Fee Act.
|
|
|
The partnership reflects a focus on precision oncology, seeking to enhance patient selection and assess treatment responses.
|
|
|
This deal falls into the wider pipeline restocking trend in pharma, as companies look to protect their revenue amid looming patent expirations.
|
|
|
Replimune’s RP1 is based on a genetically engineered herpes simplex virus intended to stimulate an anti-tumour immune response.
|
|
